Michael Covarrubias - Rezolute Senior Management

Rezolute Management Efficiency

The company has return on total asset (ROA) of (0.3433) % which means that it has lost $0.3433 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5773) %, meaning that it created substantial loss on money invested by shareholders. Rezolute's management efficiency ratios could be used to measure how well Rezolute manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2024. Return On Capital Employed is likely to gain to -0.54 in 2024. At this time, Rezolute's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 139.4 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 69.1 K in 2024.

Similar Executives

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Rezolute operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 42 people. Rezolute (RZLT) is traded on NASDAQ Exchange in USA. It is located in 275 Shoreline Drive, Redwood City, CA, United States, 94065 and employs 59 people. Rezolute is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Rezolute Leadership Team

Rezolute Stock Performance Indicators

Additional Tools for Rezolute Stock Analysis